Denali Therapeutics Inc. Payments to Acquire Marketable Securities
Denali Therapeutics Inc. (DNLI) reported Payments to Acquire Marketable Securities of $394.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Denali Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $271.50M.
- Denali Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $123.07M, a 10.77% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $252.71M, a 45.48% increase year-over-year.
- Denali Therapeutics Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $50.63M, a 49.60% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire marketable securities for fiscal 2025 was $441.26M, a 64.12% decline from fiscal 2024.
- Denali Therapeutics Inc. payments to acquire marketable securities for fiscal 2024 was $1.23B, a 32.18% decline from fiscal 2023.
- Denali Therapeutics Inc. payments to acquire marketable securities for fiscal 2023 was $1.81B, a 62.66% increase from fiscal 2022.
- Denali Therapeutics Inc. payments to acquire marketable securities for fiscal 2022 was $1.12B, a 21.64% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $271.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $394.58M 10-Q · filed 2026-08-06 | $647.29M derived: sum of 3 quarters · filed 2026-08-06 | $697.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $123.07M 10-Q · filed 2026-05-07 | $375.78M derived: sum of 2 quarters · filed 2026-05-07 | $426.41M derived: sum of 3 quarters · filed 2026-05-07 | $426.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $252.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $303.34M derived: sum of 2 quarters · filed 2026-02-26 | $303.34M derived: sum of 3 quarters · filed 2026-08-06 | $441.26M 10-K · filed 2026-02-26 |
| 2025-09-30 | $50.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $50.63M derived: sum of 2 quarters · filed 2026-08-06 | $188.56M 10-Q · filed 2025-11-06 | $362.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $137.93M 10-Q · filed 2026-08-06 | $311.63M derived: sum of 3 quarters · filed 2026-08-06 | $412.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $137.93M 10-Q · filed 2026-05-07 | $311.63M derived: sum of 2 quarters · filed 2026-05-07 | $412.09M derived: sum of 3 quarters · filed 2026-05-07 | $533.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $173.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $274.16M derived: sum of 2 quarters · filed 2026-02-26 | $395.81M derived: sum of 3 quarters · filed 2026-02-26 | $1.23B 10-K · filed 2026-02-26 |
| 2024-09-30 | $100.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $222.11M derived: sum of 2 quarters · filed 2025-11-06 | $1.06B 10-Q · filed 2025-11-06 | $1.47B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $121.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $955.80M 10-Q · filed 2025-08-11 | $1.37B derived: sum of 3 quarters · filed 2026-02-26 | $1.87B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $834.16M 10-Q · filed 2025-05-06 | $1.25B derived: sum of 2 quarters · filed 2026-02-26 | $1.75B derived: sum of 3 quarters · filed 2026-02-26 | $2.12B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $413.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $911.86M derived: sum of 2 quarters · filed 2026-02-26 | $1.29B derived: sum of 3 quarters · filed 2026-02-26 | $1.81B 10-K · filed 2026-02-26 |
| 2023-09-30 | $498.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $876.27M derived: sum of 2 quarters · filed 2024-11-06 | $1.40B 10-Q · filed 2024-11-06 | $1.89B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $378.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $901.84M 10-Q · filed 2024-08-01 | $1.39B derived: sum of 3 quarters · filed 2025-02-27 | $1.51B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $523.71M 10-Q · filed 2024-05-07 | $1.01B derived: sum of 2 quarters · filed 2025-02-27 | $1.13B derived: sum of 3 quarters · filed 2025-02-27 | $1.27B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $486.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $609.58M derived: sum of 2 quarters · filed 2025-02-27 | $750.70M derived: sum of 3 quarters · filed 2025-02-27 | $1.12B 10-K · filed 2025-02-27 |
| 2022-09-30 | $122.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $263.99M derived: sum of 2 quarters · filed 2023-11-07 | $628.33M 10-Q · filed 2023-11-07 | $859.78M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $141.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $505.46M 10-Q · filed 2023-08-08 | $736.91M derived: sum of 3 quarters · filed 2024-02-28 | $1.08B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $364.34M 10-Q · filed 2023-05-08 | $595.78M derived: sum of 2 quarters · filed 2024-02-28 | $939.98M derived: sum of 3 quarters · filed 2024-02-28 | $1.32B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $231.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $575.64M derived: sum of 2 quarters · filed 2024-02-28 | $959.83M derived: sum of 3 quarters · filed 2024-02-28 | $1.42B 10-K · filed 2024-02-28 |
| 2021-09-30 | $344.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $728.39M derived: sum of 2 quarters · filed 2022-11-03 | $1.19B 10-Q · filed 2022-11-03 | $1.79B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $384.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $847.30M 10-Q · filed 2022-08-08 | $1.45B derived: sum of 3 quarters · filed 2023-02-27 | $1.81B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $463.11M 10-Q · filed 2022-05-05 | $1.06B derived: sum of 2 quarters · filed 2023-02-27 | $1.42B derived: sum of 3 quarters · filed 2023-02-27 | $1.60B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $597.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $961.86M derived: sum of 2 quarters · filed 2023-02-27 | $1.13B derived: sum of 3 quarters · filed 2023-02-27 | $1.29B 10-K · filed 2023-02-27 |
| 2020-09-30 | $363.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $534.37M derived: sum of 2 quarters · filed 2021-11-04 | $687.52M 10-Q · filed 2021-11-04 | $838.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $170.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $323.61M 10-Q · filed 2021-08-04 | $474.16M derived: sum of 3 quarters · filed 2022-02-28 | $549.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $153.16M 10-Q · filed 2021-05-05 | $303.71M derived: sum of 2 quarters · filed 2022-02-28 | $378.82M derived: sum of 3 quarters · filed 2022-02-28 | $413.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $150.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $225.67M derived: sum of 2 quarters · filed 2022-02-28 | $259.89M derived: sum of 3 quarters · filed 2022-02-28 | $369.70M 10-K · filed 2022-02-28 |
| 2019-09-30 | $75.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $109.33M derived: sum of 2 quarters · filed 2020-11-05 | $219.14M 10-Q · filed 2020-11-05 | $376.43M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $34.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $144.03M 10-Q · filed 2020-08-07 | $301.32M derived: sum of 3 quarters · filed 2021-02-26 | $340.27M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $109.81M 10-Q · filed 2020-05-07 | $267.10M derived: sum of 2 quarters · filed 2021-02-26 | $306.05M derived: sum of 3 quarters · filed 2021-02-26 | $339.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $157.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $196.24M derived: sum of 2 quarters · filed 2021-02-26 | $229.89M derived: sum of 3 quarters · filed 2021-02-26 | $557.93M 10-K · filed 2021-02-26 |
| 2018-09-30 | $38.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $72.60M derived: sum of 2 quarters · filed 2019-11-06 | $400.64M 10-Q · filed 2019-11-06 | $533.77M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $33.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $361.69M 10-Q · filed 2019-08-06 | $494.82M derived: sum of 3 quarters · filed 2020-02-27 | $513.32M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $328.04M 10-Q · filed 2019-05-08 | $461.17M derived: sum of 2 quarters · filed 2020-02-27 | $479.67M derived: sum of 3 quarters · filed 2020-02-27 | $490.88M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $133.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $151.63M derived: sum of 2 quarters · filed 2020-02-27 | $162.84M derived: sum of 3 quarters · filed 2020-02-27 | $179.79M 10-K · filed 2020-02-27 |
| 2017-09-30 | $18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $29.70M derived: sum of 2 quarters · filed 2018-11-08 | $46.65M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $11.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $28.16M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $16.95M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $226.37M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |